research Why we should treat COVID-19 Long-Hauler Syndromes with Convalescent Plasma; Contained Suppressive Exosomes are likely COVID antigen-specific
Convalescent Plasma Therapy may help treat COVID-19 Long-Hauler symptoms.
Search
for
Sort by
Research
840-870 / 1000+ results 
research Oral administration of berberine represses macrophage activation-associated benign prostatic hyperplasia: a pivotal involvement of the NF-κB
Berberine may reduce prostate enlargement by blocking inflammation.
research Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism
Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.
research T helper type 2 immune response in alopecia areata
Allergies, especially dust mite allergy, may worsen alopecia areata, and desensitization could help reduce its severity.
research A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab
Adalimumab helped control a child's severe eye disease when other treatments failed.
research CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.
CS12192 effectively treats alopecia areata with better safety than current options.
research Sycosis Barbae Treated With Bimekizumab
Bimekizumab effectively treated a man's chronic beard hair loss.
research 264 CCR5 blockade shows prevention of alopecia areata development as well as improvement of alopecia areata
Blocking CCR5 can prevent and improve hair loss in alopecia areata.
research Glibenclamide reverses cromakalim-induced anti-ischemic effect in conscious rabbits
research Botulinum toxin type A alleviates androgenetic alopecia by inhibiting apoptosis of dermal papilla cells via targeting circ_0135062/miR-506-3p/Bax axis
Botulinum toxin type A helps treat hair loss by stopping cell death in hair follicles through a process involving certain non-coding RNAs and a protein called Bax.
research Anti-CD44-mediated blockade of leukocyte migration in skin-associated immune diseases
Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.
research Characterization of LHTric-1, a new monospecific monoclonal antibody to the trichocyte keratin Ha1
LHTric-1 is a specific antibody useful for studying hair and nail formation.
research Successful rapid subcutaneous desensitization to anakinra in a case of delayed‐type hypersensitivity reaction
A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
research Immune-Mediated Skin Reactions Induced by Recombinant Antibodies and Other TNF-Alpha Inhibitors
TNF-alpha inhibitors can cause various immune-related skin issues.
research Redox-Modulatory and MET-Inhibitory Triad: Synergistic Cytotoxicity of L-cysteine, NAC, and MET Inhibition in Cervical Cancer Cells
Combining L-cysteine, NAC, and a MET inhibitor significantly kills cervical cancer cells.
research Structural characterization and bioactive screening of two homogeneity proteins from Tianshan red deer abomasum
Proteins from Tianshan red deer abomasum have strong anti-inflammatory, anti-tumor, and antioxidant effects.
research POS0548 ACUTE AND SUBACUTE SKIN MANIFESTATIONS OF SYSTEMIC LUPUS ERYTHEMATOSUS ARE ASSOCIATED WITH AN EARLIER RESPONSE TO BELIMUMAB THAN THE CHRONIC PHENOTYPE: PRELIMINARY DATA FROM THE NEW NATION-WIDE COHORT OF BELIMUMAB IN REAL LIFE SETTING STUDY—NEW JOINT AND SKIN (BERLISS-NEJS)
Patients with acute and subacute skin lupus respond faster to belimumab than those with chronic skin lupus.
research Unusual Anti-Angiogenic Effect of Combined Hormonal Blockade
research Sintilimab-induced Alopecia Universalis in a Patient With the Anti-tumor Effect of Complete Remission After Hepatectomy
Sintilimab treatment caused hair loss but led to complete tumor remission.
research Severe steroid-dependent idiopathic angioedema with response to rituximab
A woman with severe angioedema improved significantly after treatment with rituximab.
research The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial
Both injectable contraceptives lower testosterone and SHBG levels, with NET-EN having a greater effect than DMPA-IM.
research Non-competitive androgen receptor inhibition in vitro and in vivo
Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Plasma proteome–driven identification of druggable immune regulators of alopecia areata, validated by transcriptome and single-cell mapping
Belatacept may be a promising treatment for alopecia areata.
research 448 Combined therapeutic approach: Inhibition of MMP-9 and JAK Signaling Synergistically Prevents Depigmentation in Experimental Vitiligo
Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
research Data from Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
research Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia
M50054 may help treat hepatitis and hair loss from chemotherapy.
research Immunological characteristics and histological distribution of human hair fibrous proteins studied with anti-hair keratin monoclonal antibodies HKN-2, HKN-4, and HKN-6.
Some hair proteins are specific to hair, while others are also found in skin cells.
research Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
research LB793 A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.